The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2121-2136

  Wirth, Andrew ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Large cell lymphoma; Mabthera; Radiotherapy

Indexed keywords

CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; CANCER CONTROL; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARGE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DECISION MAKING; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 36049039311     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701636468     Document Type: Review

References (141)

1. Lee, C. K. (2006) Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am, 20, pp. 471-503.
2. Nieder, C., Licht, T., Andratschke, N., Peschel, C. and Molls, M. (2003) Influence of differing radiotherapy strategies on treatment results in diffuse large-cell lymphoma: A review. Cancer Treat Rev, 29, pp. 11-19.
3. Gustavsson, A., Osterman, B. and Cavallin-Stahl, E. (2003) A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol, 42, pp. 605-619.
4. Cox, J. D., Ha, C. S., Lee, H. K., Dabaja, B. S. and Wilder, R. B. (2003) Uncertainties in contemporary treatment of aggressive lymphomas. Rays, 28, pp. 289-292.
5. Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M. and Grogan, T. M. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med, 339, pp. 21-26.
6. Horning, S. J., Weller, E., Kim, K., Earle, J. D., O'Connell, M. J. and Habermann, T. M. (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol, 22, pp. 3032-3038.
7. Reyes, F., Lepage, E., Ganem, G., Molina, T. J., Brice, P. and Coiffier, B. (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 352, pp. 1197-1205.
8. Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T. J. and Thieblemont, C. (2007) CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 25, pp. 787-792.
9. Aviles, A., Delgado, S., Ruiz, H., de la Torre, A., Guzman, R. and Talavera, A. (1996) Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy. Eur J Cancer B Oral Oncol, 32, pp. 19-23.
10. Aviles, A., Fernandezb, R., Perez, F., Nambo, M. J., Neri, N. and Talavera, A. (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma, 45, pp. 1385-1389.
11. Aviles, A., Neri, N., Delgado, S., Perez, F., Nambo, M. J. and Cleto, S. (2005) Residual disease after chemotherapy in aggressive malignant lymphoma: The role of radiotherapy. Med Oncol, 22, pp. 383-387.
12. Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P. and Evans, E. (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet, 366, pp. 2087-2106.
13. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage (1982) The non-hodgkin's lymphoma pathologic classification project. Cancer, 49, pp. 2112-2135.
14. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. and Cleary, M. L. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, pp. 1361-1392.
15. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G. and Muller-Hermelink, H. K. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
16. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P. and Young, R. C. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7, pp. 1630-1636.
17. A predictive model for aggressive non-Hodgkin's lymphoma (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
18. Lossos, I. S. and Morgensztern, D. (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, pp. 995-1007.
19. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. and Horning, S. J. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
20. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. and Guermazi, A. (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 25, pp. 571-578.
21. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M. and Imrie, K. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 7, pp. 379-391.
22. Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K. and Hoskins, P. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, pp. 1857-1861.
23. Coiffier, B. (2005) Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep, 4, pp. 7-14.
24. Tsang, R. W. and Gospodarowicz, M. K. (2001) Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol, 80, pp. B66-B72.
25. Berrios-Rivera, J. P., Fang, S., Cabanillas, M. E., Cabanillas, F. and Du, X. L. (2007) Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol, 30, pp. 163-171.
26. Longo, D. L. (1989) Combined modality therapy for localized aggressive lymphoma: Enough or too much?. J Clin Oncol, 7, pp. 1179-1181.
27. Miller, T. P., Spier, C. M. and Rimsza, L. (2006) Diffuse aggressive histologies of non-hodgkin lymphoma: Treatment and biology of limited disease. Semin Hematol, 43, pp. 207-212.
28. Miller, T. P. (2004) The limits of limited stage lymphoma. J Clin Oncol, 22, pp. 2982-2984.
29. Ng, A. K. and Mauch, P. M. (2007) Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol, 25, pp. 757-759.
30. Friedberg, J. W. (2006) Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol, 7, pp. 357-359.
31. Shenkier, T. N., Voss, N., Fairey, R., Gascoyne, R. D., Hoskins, P. and Klasa, R. (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency. J Clin Oncol, 20, pp. 197-204.
32. Tondini, C., Zanini, M., Lombardi, F., Bengala, C., Rocca, A. and Giardini, R. (1993) Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol, 11, pp. 720-725.
33. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J. and de Groot, T. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 13, pp. 1356-1363.
34. Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J. and Timothy, A. R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 16, pp. 1514-1523.
35. Ng, A. P., Wirth, A., Seymour, J. F., Lee, M., Hogg, A. and Januszewicz, H. (2007) Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma, 48, pp. 596-600.
36. Sutcliffe, S. B., Gospodarowicz, M. K., Brown, T. C., Chua, T., Bean, H. A. and Bush, R. S. (1985) Role of radiation therapy in localized non-Hodgkin's Lymphoma. Radiother Oncol, 4, pp. 211-223.
37. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M. and Mize, E. M. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, pp. 1002-1006.
38. van der Maazen, R. W., Noordijk, E. M., Thomas, J., Raemaekers, J. M. and Meerwaldt, J. H. (1998) Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol, 49, pp. 1-7.
39. Miller, T. P. and Jones, S. E. (1979) Chemotherapy of localised histiocytic lymphoma. Lancet, 1, pp. 358-360.
40. Connors, J. M., Klimo, P., Fairey, R. N. and Voss, N. (1987) Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med, 107, pp. 25-30.
41. Cabanillas, F., Bodey, G. P. and Freireich, E. J. (1980) Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer, 46, pp. 2356-2359.
42. Cabanillas, F. (1985) Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. Hematol Oncol, 3, pp. 25-31.
43. Jones, S. E., Miller, T. P. and Connors, J. M. (1989) Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol, 7, pp. 1186-1191.
44. Miller, T., LeBlanc, M., Spier, C., Chase, E. and Fischer, R. (2001) CHOP alone compared to CHOP plus radiotherapy for early-stage aggressive non-Hodgkin lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood, 98, p. 724a.
45. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R. and Bosly, A. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, pp. 4284-4289.
46. Bernard, M., Cartron, G., Rachieru, P., LeMevel, A., Branger, B. and Maignan, C Le (2005) Long-term outcome of localized high-.grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: Results of a GOELAMS study. Haematologica, 90, pp. 802-809.
47. Shikama, N., Oguchi, M., Isobe, K., Nakamura, K., Tamaki, Y. and Hasegawa, M. (2006) A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 66, pp. 217-222.
48. Miller, T., Unger, J., Spier, C. and Stea, B. (2004) Effect of adding Rituximab to three cycles of CHOP plus involved field radiotherapy for limited stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood, 104, pp. 48a-49a.
49. Longo, D. L., Glatstein, E., Duffey, P. L., Ihde, D. C., Hubbard, S. M. and Fisher, R. I. (1989) Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol, 7, pp. 1295-1302.
50. Eich, H. T., Staar, S., Gossmann, A., Hansemann, K., Skripnitchenko, R. and Kocher, M. (2004) Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys, 58, pp. 1121-1127.
51. Aleman, B. M., Girinsky, T., van der Maazen, R. W., Strijk, S., Meijnders, P. and Bortolus, R. (2005) Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884). Int J Radiat Oncol Biol Phys, 63, pp. 1184-1190.
52. Ganem, G., Reyes, F., Lepage, E., Gaillerd, I., Munck, J. and Morel, P. (2001) Three CHOP followed by radiotherapy versus a more intensive Chemotherapy alone in low risk localised aggressive non-Hodgkin's lymphoma: Preliminary results of the GELA LNH 93-1 study. Int journal of radiat oncol Biol Phys, 51, p. 67.
53. Gospodarowicz, M. K. and Sutcliffe, S. B. (1995) The extranodal lymphomas. Semin Radiat Oncol, 5, pp. 281-300.
54. Newton, R., Ferlay, J., Beral, V. and Devesa, S. S. (1997) The epidemiology of non-Hodgkin's lymphoma: Comparison of nodal and extra-nodal sites. Int J Cancer, 72, pp. 923-930.
55. Lopez-Guillermo, A., Colomo, L., Jimenez, M., Bosch, F., Villamor, N. and Arenillas, L. (2005) Diffuse large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol, 23, pp. 2797-2804.
56. Ferreri, A. J., Batchelor, T., Zucca, E., Cavalli, F. and Armitage, J. (2003) International Collaborative Group against primary CNS lymphomas. J Clin Oncol, 21, pp. 1649-1650.
57. Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M. and Abrey, L. E. (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol, 24, pp. 4570-4574.
58. Batchelor, T. and Loeffler, J. S. (2006) Primary CNS lymphoma. J Clin Oncol, 24, pp. 1281-1288.
59. Bessell, E. M., Lopez-Guillermo, A., Villa, S., Verger, E., Nomdedeu, B. and Petit, J. (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol, 20, pp. 231-236.
60. Fisher, B., Seiferheld, W., Schultz, C., DeAngelis, L., Nelson, D. and Schold, S. C. (2005) Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol, 74, pp. 201-205.
61. Yahalom, J., Shah, G. D., Lai, R. K., Correa, D. D., DeAngelis, L. M. and Abrey, L. (2006) Reduced-dose whole brain radiotherapy following complete response to immuno-chemotherapy in patients with primary CNS lymphoma. Int J Radiat Oncol Biol Phys, 66, p. S84.
62. Zucca, E., Conconi, A., Mughal, T. I., Sarris, A. H., Seymour, J. F. and Vitolo, U. (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol, 21, pp. 20-27.
63. Vitolo, U., Zucca, E., Martelli, M., Chiapella, A., Baldi, I. and Balzarrotti, M. (2006) Primary diffuse large B-cell lymphoma of the testis: A prospective study of rituximab (R)-CHOP with CNS and contralateral testis prohylaxis. Results of IELSG 10 study. Blood, 108, p. 65a.
64. Ryan, G., Martinelli, G., Yuen, K. and Seymour, J. (2005) Primary non-Hodgkin's lymphoma of the breast: First report of the multicentre retrospective study of the International Extranodal Lymphoma Study Group (IELSG-15). J Clin Oncol, 23, p. 6575.
65. Wong, W. W., Schild, S. E., Halyard, M. Y. and Schomberg, P. J. (2002) Primary non-Hodgkin lymphoma of the breast: The Mayo clinic experience. J Surg Oncol, 80, pp. 19-25.
66. Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A. and Horning, S. (2007) Non-Hodgkin lymphoma of the breast. Cancer, 110, pp. 25-30.
67. Cortelazzo, S., Mian, M., Rossi, A. and Oldani, E. (2007) Primary extranodal diffuse large B-cell lymphomas arising in distinct sites of head and neck have different clinical characteristics and outcome. Haematologica, 92
68. Christie, D., Gracia, E., Gospodarowicz, M. and Martinelli, G. (2007) Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the International Extranodal Lymphoma Study Group. Haematologica, 92
69. Park, Y. H., Lee, S. H., Kim, W. S., Bang, S. M., Ryoo, B. Y. and Yang, S. H. (2006) CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. Leuk Lymphoma, 47, pp. 1253-1259.
70. Choi, I. S., Kim, J. H., Rhu, M. H., Kim, T. Y. and Heo, D. S. (2005) Management of gastric lymphoma with chemotherapy alone. Leuk Lymphoma, 46, pp. 1329-1335.
71. Wohrer, S., Troch, M. and Raderer, M. (2006) Treatment of localized primary gastric lymphoma. J Clin Oncol, 24, p. 2682.
72. Wohrer, S., Puspok, A., Drach, J., Hejna, M., Chott, A. and Raderer, M. (2004) Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol, 15, pp. 1086-1090.
73. Ishikura, S., Tobinai, K., Ohtsu, A., Nakamura, S., Yoshino, T. and Oda, I. (2005) Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci, 96, pp. 349-352.
74. van Besien, K., Kelta, M. and Bahaguna, P. (2001) Primary mediastinal B-cell lymphoma: A review of pathology and management. J Clin Oncol, 19, pp. 1855-1864.
75. Savage, K. J. (2006) Primary mediastinal large B-cell lymphoma. Oncologist, 11, pp. 488-495.
76. Savage, K. J., Al-Rajhi, N., Voss, N., Paltiel, C., Klasa, R., Gascoyne, R. D. and Connors, J. M. (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: The British Columbia experience. Ann Oncol, 17, pp. 123-130.
77. Todeschini, G., Secchi, S., Morra, E., Vitolo, U., Orlandi, E. and Pasini, F. (2004) Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer, 90, pp. 372-376.
78. Zinzani, P. L., Martelli, M., Magagnoli, M., Pescarmona, E., Scaramucci, L. and Palombi, F. (1999) Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood, 94, pp. 3289-3293.
79. Zinzani, P. L., Martelli, M., Bertini, M., Gianni, A. M., Devizzi, L. and Federico, M. (2002) Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica, 87, pp. 1258-1264.
80. Ott, G. and Rosenwald, A. Extranodal diffuse large B-cell lymphoma-an organotypic disease?. Pathologe
81. Fisher, R. I., DeVita Jr, V. T., Johnson, B. L., Simon, R. and Young, R. C. (1977) Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med, 63, pp. 177-182.
82. Jagannath, S., Velasquez, W. S., Tucker, S. L., Fuller, L. M., McLaughlin, P. W. and Manning, J. T. (1986) Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol, 4, pp. 859-865.
83. Coiffier, B., Gisselbrecht, C., Vose, J. M., Tilly, H., Herbrecht, R. and Bosly, A. (1991) Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol, 9, pp. 211-219.
84. Rodriguez, J., Cabanillas, F., McLaughlin, P., Swan, F., Rodriguez, M. and Hagemeister, F. (1992) A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol, 3, pp. 711-717.
85. Lopez-Guillermo, A., Montserrat, E., Reverter, J. C., Cervantes, F., Escoda, L. and Tassies, D. (1993) Large-cell lymphoma: A study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma, 10, pp. 101-109.
86. Pfreunschuh (2007) Prognostic significance of maximal tumor size (MTS) in young patients with good-prognosis diffuse large B-cell lymphoma (DLBCL) treated with CHOP-like chemotherapy with and without rituximab: Analysis of the Mabthera International Trial Group (MInT) study. J Clin Oncol, 25, p. 454s.
87. Shipp, M. A., Klatt, M. M., Yeap, B., Jochelson, M. S., Mauch, P. M. and Rosenthal, D. S. (1989) Patterns of relapse in large-cell lymphoma patients with bulk disease: Implications for the use of adjuvant radiation therapy. J Clin Oncol, 7, pp. 613-618.
88. Morgan, S., Wirth, A., Wolf, M., Stone, J., Reynolds, J. and Prince, H. (2004) Patterns of Failure in ALLG Intermediate Grade Non-Hodgkin's Lymphoma (intNHL) Studies 2004. Proceedings of the Haematology Society of Australia and New Zealand, p. 109.
89. Rube, C., Nguyen, T. P., Kloss, M., Loeffler, M., Trumper, L. and Pfreunschuh, M. (2001) Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Hematol, 80, pp. B84-B85.
90. Schlembach, P. J., Wilder, R. B., Tucker, S. L., Ha, C. S., Rodriguez, M. A. and Hess, M. A. (2000) Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys, 48, pp. 1107-1110.
91. Ferreri, A. J., Dell'Oro, S., Reni, M., Ceresoli, G. L., Cozzarini, C. and Ponzoni, M. (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology, 58, pp. 219-226.
92. Wilder, R. B., Rodriguez, M. A., Tucker, S. L., Ha, C. S., Hess, M. A. and Cabanillas, F. F. (2001) Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys, 50, pp. 743-749.
93. Moser, E. C., Kluin-Nelemans, H. C., Carde, P., Meerwaldt, J. H., Tirelli, U. and Aleman, B. M. (2006) Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 66, pp. 1168-1177.
94. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
95. Zijlstra, J. M., der Werf, G Lindauer-van, Hoekstra, O. S., Hooft, L., Riphagen, I. I. and Huijgens, P. C. (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica, 91, pp. 522-529.
96. Brepoels, L., Stroobants, S. and Verhoef, G. (2007) PET and PET/CT for response evaluation in lymphoma: Current practice and developments. Leuk Lymphoma, 48, pp. 270-282.
97. Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y. and Wooldridge, J. E. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 23, pp. 4652-4661.
98. Kahn, S. T., Flowers, C., Lechowicz, M. J., Hollenbach, K. and Johnstone, P. A. (2006) Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: Implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys, 66, pp. 961-965.
99. Aref, A., Mohammad, R., Yudelev, M., Choudhuri, R., Strowbridge, A. and Orton, C. (1999) Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines. Radiat Oncol Investig, 7, pp. 158-162.
100. Aref, A., Narayan, S., Tekyi-Mensah, S., Varterasian, M., Dan, M. and Eilender, D. (1999) Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma. Radiat Oncol Investig, 7, pp. 186-191.
101. Kamath, S. S., Marcus Jr, R. B., Lynch, J. W. and Mendenhall, N. P. (1999) The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 44, pp. 563-568.
102. Fuller, L. M., Krasin, M. J., Velasquez, W. S., Allen, P. K., McLaughlin, P. and Rodriguez, M. A. (1995) Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys, 31, pp. 3-11.
103. Moskowitz, C. (2006) Phase II Trial: Dose dense CHOP followed by risk adapted consolidation with either ICE or ICE/ASCT: Based on the results of biopsy confirmed abnormal restaging interim PET scan. Blood, 106, p. 582a.
104. Ng, A. K. and Mauch, P. M. (2004) Late complications of therapy of Hodgkin's disease: Prevention and management. Curr Hematol Rep, 3, pp. 27-33.
105. Franklin, J., Pluetschow, A., Paus, M., Specht, L., Anselmo, A. P. and Aviles, A. (2006) Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials. Ann Oncol, 17, pp. 1749-1760.
106. Moser, E. C., Noordijk, E. M., Carde, P., Tirelli, U., Baars, J. W. and Thomas, J. (2005) Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma, 6, pp. 122-130.
107. Moser, E. C., Noordijk, E. M., van Leeuwen, F. E., Baars, J. W., Thomas, J. and Carde, P. (2006) Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica, 91, pp. 1481-1488.
108. Moser, E. C., Noordijk, E. M., van Leeuwen, F. E., Cessie, S le, Baars, J. W. and Thomas, J. (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood, 107, pp. 2912-2919.
109. Tward, J. D., Wendland, M. M., Shrieve, D. C., Szabo, A. and Gaffney, D. K. (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107, pp. 108-115.
110. Girinsky, T., van der Maazen, R., Specht, L., Aleman, B., Poortmans, P. and Lievens, Y. (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol, 79, pp. 270-277.
111. Koh, E. S., Tran, T. H., Heydarian, M., Sachs, R. K., Tsang, R. W. and Brenner, D. J. (2007) A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk. Radiat Oncol, 2, p. 13.
112. Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E. and Holowaty, E. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama, 290, pp. 465-475.
113. Friedman, D. L. and Constine, L. S. (2006) Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw, 4, pp. 249-257.
114. Das, P., Ng, A. K., Earle, C. C., Mauch, P. M. and Kuntz, K. M. (2006) Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: Decision analysis and cost-effectiveness analysis. Ann Oncol, 17, pp. 785-793.
115. Apter, S., Shemesh, J., Raanani, P., Portnoy, O., Thaler, M. and Zissin, R. (2006) Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: Computed tomography detection and clinical correlation. Coron Artery Dis, 17, pp. 145-151.
116. Faulkner, K. and Law, J. (2005) Mammographic breast cancer screening for women previously treated with high breast doses for diseases such as Hodgkin's. Radiat Prot Dosimetry, 117, pp. 330-333.
117. Patel, D. A., Kochanski, J., Suen, A. W., Fajardo, L. F., Hancock, S. L. and Knox, S. J. (2006) Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer, 106, pp. 718-725.
118. Amadori, D. and Ronconi, S. (2005) Secondary lung tumors in hematological patients. Semin Respir Crit Care Med, 26, pp. 520-526.
119. Koh, E. S., Sun, A., Tran, T. H., Tsang, R., Pintilie, M. and Hodgson, D. C. (2006) Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 66, pp. 223-228.
120. Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R. and Pierce, L. J. (2006) Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer. J Clin Oncol, 24, pp. 2779-2785.
121. Dorresteijn, L. D., Stewart, F. A. and Boogerd, W. (2006) Stroke as a late treatment effect of Hodgkin's disease. J Clin Oncol, 24, p. 1480.
122. Mantini, G., Smaniotto, D., Balducci, M., Dinapoli, N., Campitelli, M. and Corvari, B. (2005) Radiation-induced cardiovascular disease: impact of dose and volume. Rays, 30, pp. 157-168.
123. Yahalom, J. (2005) Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol, pp. 90-97.
124. Lee, Y. K., Cook, G., Flower, M. A., Rowbottom, C., Shahidi, M. and Sharma, B. (2004) Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol, 73, pp. 277-283.
125. Della Biancia, C., Hunt, M., Furhang, E. and Yahalom, J. (2005) Radiation treatment planning techniques for lymphoma of the stomach. Int J Radiat Oncol Biol Phys, 62, pp. 745-751.
126. Nieder, C., Schill, S., Kneschaurek, P. and Molls, M. (2007) Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol, 82, pp. 301-307.
127. Goodman, K. A., Toner, S., Hunt, M., Wu, E. J. and Yahalom, J. (2005) Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys, 62, pp. 198-206.
128. Beasley, M., Driver, D. and Dobbs, H. J. (2005) Complications of radiotherapy: improving the therapeutic index. Cancer Imaging, 5, pp. 78-84.
129. Dirix, P., Nuyts, S. and Bogaert, W Van den (2006) Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer, 107, pp. 2525-2534.
130. Wilder, R. B., Tucker, S. L., Ha, C. S., Rodriguez, M. A., Hess, M. A. and Cabanillas, F. F. (2001) Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys, 49, pp. 17-22.
131. Mirza, M. R., Brincker, H. and Specht, L. (1992) The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma. Crit Rev Oncol Hematol, 12, pp. 217-229.
132. Hoskin, P. (2005) Radiation dose in non-Hodgkin's lymphoma: preliminary results of a UK NCRN randomised trial. Ann Oncol, 16
133. Isobe, K., Kawakami, H., Tamaru, J., Yasuda, S., Uno, T. and Aruga, T. (2003) Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: a prospective study. Leuk Lymphoma, 44, pp. 1535-1539.
134. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
135. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R. and Ferme, C. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 23, pp. 4117-4126.
136. Armitage, J. O. (2007) How I treat patients with diffuse large B-Cell lymphoma. Blood
137. Ferreri, A. J. and Reni, M. (2007) Primary central nervous system lymphoma. Crit Rev Oncol Hematol, 63, pp. 257-268.
138. Hamlin, P. A., Portlock, C. S., Straus, D. J., Noy, A., Singer, A. and Horwitz, S. M. (2005) Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol, 130, pp. 691-699.
139. Lorigan, P., Radford, J., Howell, A. and Thatcher, N. (2005) Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol, 6, pp. 773-779.
140. Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E. and Ansell, S. M. (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 23, pp. 7614-7620.
141. Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W. and Horwich, A. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst, 99, pp. 206-214.